Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Immunocore Holdings PLC Sponsored ADR (IMCR : NSDQ)
 
 • Company Description   
Immunocore Holdings plc is a late-stage biotechnology company. It engages in development of a novel class of T cell receptor bispecific immunotherapies designed to treat diseases, including cancer, infectious and autoimmune disease. Immunocore Holdings plc is based in Abingdon, the United Kingdom.

Number of Employees: 493

 
 • Price / Volume Information   
Yesterday's Closing Price: $32.75 Daily Weekly Monthly
20 Day Moving Average: 438,855 shares
Shares Outstanding: 50.23 (millions)
Market Capitalization: $1,645.15 (millions)
Beta: 0.77
52 Week High: $41.54
52 Week Low: $23.15
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -13.13% -16.71%
12 Week 25.38% 9.87%
Year To Date 11.02% 4.85%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
92 PARK DRIVE MILTON PARK ABINGDON
-
OXFORDSHIRE,X0 OX14 4RY
GBR
ph: 44-12-3543-8600
fax: -
ir@immunocore.com http://www.immunocore.com
 
 • General Corporate Information   
Officers
Bahija Jallal - Chief Executive Officer and Director
Professor Sir John Bell - Chairman of the Board of Directors
Travis Coy - Chief Financial Officer
John Goll - Finance and Chief Accounting Officer
Roy S. Herbst - Director

Peer Information
Immunocore Holdings PLC Sponsored ADR (CORR.)
Immunocore Holdings PLC Sponsored ADR (RSPI)
Immunocore Holdings PLC Sponsored ADR (CGXP)
Immunocore Holdings PLC Sponsored ADR (BGEN)
Immunocore Holdings PLC Sponsored ADR (GTBP)
Immunocore Holdings PLC Sponsored ADR (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 45258D105
SIC: 2836
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/25
Next Expected EPS Date: 08/14/25
Share - Related Items
Shares Outstanding: 50.23
Most Recent Split Date: (:1)
Beta: 0.77
Market Capitalization: $1,645.15 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.26 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-0.70 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 7.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/14/25  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 4.34
Price/Cash Flow: -
Price / Sales: 4.93
EPS Growth
vs. Year Ago Period: 120.41%
vs. Previous Quarter: 121.28%
Sales Growth
vs. Year Ago Period: 33.16%
vs. Previous Quarter: 11.69%
ROE
06/30/25 - -
03/31/25 - -5.86
12/31/24 - -14.02
ROA
06/30/25 - -
03/31/25 - -2.09
12/31/24 - -4.97
Current Ratio
06/30/25 - -
03/31/25 - 6.36
12/31/24 - 4.38
Quick Ratio
06/30/25 - -
03/31/25 - 6.31
12/31/24 - 4.36
Operating Margin
06/30/25 - -
03/31/25 - -6.48
12/31/24 - -16.47
Net Margin
06/30/25 - -
03/31/25 - -6.48
12/31/24 - -16.47
Pre-Tax Margin
06/30/25 - -
03/31/25 - -6.83
12/31/24 - -17.07
Book Value
06/30/25 - -
03/31/25 - 7.54
12/31/24 - 7.20
Inventory Turnover
06/30/25 - -
03/31/25 - 0.66
12/31/24 - 0.62
Debt-to-Equity
06/30/25 - -
03/31/25 - 1.03
12/31/24 - 1.08
Debt-to-Capital
06/30/25 - -
03/31/25 - 50.85
12/31/24 - 52.01
 

Powered by Zacks Investment Research ©